<DOC>
	<DOCNO>NCT02686476</DOCNO>
	<brief_summary>Fatty liver disease increasingly recognize health problem patient type 2 diabetes mellitus ( T2DM ) . Sodium glucose co-transporter type 2 ( SGLT-2 ) inhibitors new class anti-diabetic agent cause weight loss induce glycosuria . The effect SGLT-2 inhibitor liver fat content evaluate . Empagliflozin orally active , selective inhibitor SGLT-2 . We hypothesize Empagliflozin , add standard care T2DM , would improve fatty liver disease . Therefore , present study plan evaluate effect Empagliflozin liver fat content .</brief_summary>
	<brief_title>Effect Empagliflozin Liver Fat Content Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Fatty liver disease increasingly recognize health problem patient type 2 diabetes mellitus ( T2DM ) . Sodium glucose co-transporter type 2 ( SGLT-2 ) inhibitors new class anti-diabetic agent cause weight loss induce glycosuria . The effect SGLT-2 inhibitor liver fat content evaluate . Empagliflozin orally active , selective inhibitor SGLT-2 . We hypothesize Empagliflozin , add standard care T2DM , would improve fatty liver disease . Therefore , present study plan evaluate effect Empagliflozin liver fat content . Review literature Empagliflozin selective SGLT-2 inhibitor , recently approve U.S. FDA use patient T2DM . Empagliflozin patient type 2 diabetes provide sustained glycemic control weight loss 90 week generally well tolerate ( 1 ) . Another study demonstrate Empagliflozin patient T2DM result reduction HbA1c fast plasma glucose ( FPG ) , reduction body weight compare placebo . Empagliflozin well tolerate favorable safety profile ( 2 ) . Some congener class molecule see reduce liver fat content rat model . However , effect drug liver fat content human evaluate . Research question Does Empagliflozin reduce liver fat content patient T2DM fatty liver disease ? Aim study To study effect Empagliflozin liver fat content patient T2DM Primary objective 1 . To evaluate change liver fat content baseline week 12 Secondary objective 2 . To evaluate change baseline pancreatic fat content , visceral fat subcutaneous fat content 12 week Material Methods Ethical considerations The trial protocol submit Medanta ethic committee approval . The trial conduct accordance principle Declaration Helsinki Good Clinical Practice guideline . All patient provide write informed consent participation . Patients study area A total 100 patient enrol study . Consecutive patient attend outpatient Department Endocrinology Diabetes management diabetes enrol . Sample Size Calculation : Assumptions : Change liver fat content baseline week 12 Empagliflozin dose group ( m1 ) = 6.0 unit Change liver fat content baseline week 12 Standard dose group ( m2 ) = 10.0 unit Confidence level -95 % , Power - 80 % , Coefficient variation = 80 % Formula sample size calculation : n = ( Zα+Zβ ) 2 * ( σ12 + σ22 ) ) / ( m1-m2 ) 2 , Zα value normal distribution correspond desire confidence level , Zβ value Normal distribution correspond desired power , σ1 σ2 standard deviation two group . With assumption sample size per group work 50 . Randomization SPSS software use generate 100 random number 000 999 . The random number divide 2 reminder note . The reminder 0 , &amp; 1 correspond Empagliflozin dose standard dose group respectively . It ensure equal number . Opaque envelop prepared serial number top assign group inside envelope . After recruit subject envelop correspond serial number open subject assign relevant group . Statistical Analysis Plan : The analysis include profile patient different demographic , clinical laboratory parameter etc . Quantitative data present term mean standard deviation qualitative/categorical data present absolute number proportion . Cross tabulation generate chi square test use test association . Student test use comparison quantitative outcome parameter standard normal deviate test proportion . P-value &lt; 0.05 consider statistically significant . SPSS software use analysis . All patient randomize one follow intervention group : group I ( n = 50 ) : T2DM patient receive standard care T2DM ( metformin , sulfonylurea , DPP-4 inhibitor insulin , combination ) plus 10 mg Empagliflozin per day group II ( n = 50 ) : Standard care T2DM upgrade without Empagliflozin . Liver fat content , pancreatic fat content , visceral subcutaneous fat content assess magnetic resonance imaging ( MRI ) proton density fat Fraction ( PDFF ) begin study 12 week intervention . PDFF emerge lead MR-based biomarker noninvasive quantification hepatic steatosis ( 3 , 4 ) . Multiple human study show method accurately estimate PDFF liver . Based result , magnitude-based PDFF estimation method use quantify liver fat clinical practice several institution United States use biomarker drug efficacy drug toxicity National Institutes Health ( NIH ) industry clinical trial ( 5 , 6 ) . This method show accurate , reproducible ( 7 ) . Fatty liver also assess ultrasonography liver begin study 12 week intervention . On ultrasonography , severity fatty liver quantitated use score system ( 0 = fatty liver , 1 = mild fatty liver , 2 = moderate fatty liver 3 = severe fatty liver ) . Automated body composition analyzer ( BCA ) also use assess body composition 0 12 week . Laboratory workup Biochemical parameter include fast post-prandial plasma glucose , glycosylated hemoglobin ( HbA1C ) , lipid profile , hemogram , kidney function test ( urea , creatinine ) liver function test ( total fractionate bilirubin , alanine transaminase ( ALT ) , aspartate aminotransferase ( AST ) , gamma-glutamyl transpeptidase ( GGT ) , total protein , albumin ) intervention period . The primary end point 1 . Change liver fat content baseline week 12 The secondary end point 2 . Change pancreatic fat content , visceral fat subcutaneous fat content baseline week 12 Confidentiality Precautions take ensure confidentiality . Data collection form reveal name patient include study .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Patients T2DM age 40 year Fatty liver disease ( grade I USG ) Glycated A1C 7.0 % le 10.0 % Patient standard care T2DM ( metformin , sulfonylurea , DPP4 inhibitor insulin , combination ) . 1 . Serum creatinine 1.5 mg/dL 2 . Pregnancy 3 . Participants treat pioglitazone vitamin E immediate past 6 month 4 . Presence major contraindication magnetic resonance imaging ( cardiac pacemaker , claustrophobia , foreign body implant medical device ferromagnetic property ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Empagliflozin , Fatty Liver Disease</keyword>
</DOC>